Prosecution Insights
Last updated: November 12, 2026
Application No. 17/151,445

Multivalent Streptococcus Vaccines

Final Rejection §112
Filed
Jan 18, 2021
Priority
Jan 17, 2020 — provisional 62/962,535
Examiner
DEVI, SARVAMANGALA
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Inventprise LLC
OA Round
10 (Final)
66%
Grant Probability
Favorable
11-12
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
580 granted / 884 resolved
+5.6% vs TC avg
Strong +56% interview lift
Without
With
+55.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
58 currently pending
Career history
937
Total Applications
across all art units

Office Action

§112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 1) A request for continued examination under 37 C.F.R 1.114, including the fee set forth in 37 C.F.R 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 C.F.R 1.114, and the fee set forth in 37 C.F.R 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 C.F.R 1.114. Applicants’ submission filed on 04/23/26 has been entered. Applicants’ Amendment 2) Acknowledgment is made of Applicants’ amendment filed 04/23/26 in response to the final Office Action mailed 01/28/26. Status of Claims 3) Claims 1, 11, 13, 14 and 33 have been amended via the amendment filed 04/23/26. Claims 1-5, 7-9, 11-17, 20-30 and 33 are pending. Claims 1-5, 7-9, 11-17, 20, 21 and 33 are under examination. Information Disclosure Statements 4) Acknowledgment is made of Applicants’ information disclosure statements filed 05/15/26 and 04/23/26. The information referred to therein has been considered and a signed copy of the same is attached to this Office Action. Prior Citation of Title 35 Sections 5) The text of those sections of Title 35 U.S. Code not included in this action can be found in a prior Office Action References. Prior Citation of References 6) The references cited or used as prior art in support of one or more rejections in the instant Office Action and not included on an attached form PTO-892 or form PTO-1449 have been previously cited and made of record. Objection(s) Withdrawn 7) The objection to claims 1 and 11 and the specification set forth in paragraph 34 of the Office Action mailed 07/11/25 and maintained in paragraph 8 of the Office Action mailed 01/28/26 is withdrawn in light of Applicants’ claim amendments. 8) The objection to claim 33 and to the specification set forth at paragraph 9 of the Office Action mailed 01/28/26 is in light of Applicants’ claim amendments. Objection(s) to Specification and Claim(s) 9) Claim 33, as amended, and the specification are objected for the following reason(s): 35 U.S.C § 132 states that no amendment shall introduce new matter into the disclosure of the invention. 37 CFR 1.75(d)(1) provides, in part, that ‘the terms and phrases used in the claims must find clear support or antecedent basis in the description so that the meaning of the terms in the claims may be ascertainable by reference to the description.’ Claim 33, as amended, is set forth below, which lacks sufficient antecedent basis and descriptive support in the as-filed specification: PNG media_image1.png 71 580 media_image1.png Greyscale Applicants contend that the incorporation of homo multifunctional PEGylated cross linker ‘in a composition’ is disclosed in page 13 of the specification. Applicants state that claim 33 has been amended to recite that the carrier protein is covalently connected to bacterial capsular polysaccharides ‘by’ homo multifunctional PEGylated cross linkers “exactly as recited” in the specification at page 13. However, the relevant part of page 13 of the specification exactly recites the following [Emphasis in bold]: A preferred formulation of the immunogenic composition comprises at least 25 different serotypes of bacterial capsular polysaccharides of Streptococcus pneumoniae covalently connected to carrier protein through, preferably, PEGylated linker compounds. The carrier protein is covalently connected to bacterial capsular polysaccharides through a number of multifunctional PEG linkers, which may be homo-multifunctional or hetero-multi-functional, and preferably of defined lengths. Accordingly, it is suggested that Applicants replace the above-identified added limitations with the limitations --wherein the capsular polysaccharides of the S. pneumoniae serotypes indirectly coupled to the one or more carrier proteins through ......--. (B) Claims 1 and 11, as amended, include the new limitations: the “total polysaccharides and protein per dose” which the scope of which lacks sufficient antecedent basis and descriptive support in the as-filed specification. Applicants state that they have amended claims 1 and 10 to exactly confirm to the wording of claims 10 and 11. However, first, there is no pending claim 10 in the instant application since Applicants canceled claim 10 previously. Second, the original claims 10 and 11, each depend from the original claim 1, which claim 1 is significantly different from the instantly amended claim 1 both scope-wise and language-wise. With no antecedence, ‘total polysaccharides and protein per dose’ recited in those claims 10 and 11 comprised in the immunogenic composition are not required to be the specific 25 different S. pneumoniae serotype capsular polysaccharides coupled to the one or more carrier proteins comprised in the immunogenic composition of claim 1 and therefore encompass generic total polysaccharides and generic protein including those that are uncoupled and/or non-covalently coupled. If Applicants’ intention is to convey that the recited 10 micrograms or less, or 4 micrograms comprised in the dose is of the total capsular polysaccharides coupled to the one or more carrier proteins per dose, then it is suggested that Applicants replace the above-identified added limitations with the limitations --wherein the total capsular polysaccharides of the S. pneumoniae serotypes indirectly coupled to the one or more carrier proteins per dose--. Rejection(s) Withdrawn 10) The rejection of claims 13 and 14 set forth in paragraph 26(b) of the Office Action mailed 07/11/25 and maintained in paragraph 24 of the Office Action mailed 01/28/26 under 35 U.S.C § 112(b) or 35 U.S.C § 112 (pre-AIA ), second paragraph, is withdrawn in light of Applicants’ current claim amendments. 11) The rejection of claim 33 set forth in paragraph 28 of the Office Action mailed 01/28/26 under 35 U.S.C § 112(a) or 35 U.S.C § 112 (pre-AlA), first paragraph, as containing new matter is withdrawn in light of Applicants’ claim amendments. 12) The rejection of claims 1, 11, 2-5, 7-9, 12-17, 20, 21 and 33 set forth in paragraph 24 of the Office Action mailed 07/11/25 and maintained in paragraph 22 of the Office Action mailed 01/28/26 under 35 U.S.C § 112(a) or 35 U.S.C § 112 (pre-AIA ), first paragraph is withdrawn in light of Applicants’ claim amendments. Double Patenting Rejection(s) Maintained 13) The rejection of claims 1-5, 7-9, 11-17, 20, 21 and 33 set forth in paragraph 17 of the Office Action mailed 01/06/25, maintained in paragraph 21 of the Office Action mailed 07/11/25 and maintained in paragraph 19 of the Office Action mailed 01/28/26 under the judicially created doctrine of obviousness-type double patenting over claims 1-14 of US patent 12053515 B2 (of record) is maintained. Applicants contend that Applicants’ composition is directed to serotypes 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 12F, 14, 15A, 15B, 15C, 16F, 18C, 19A, 22F, 23F, 24F, 33F, and 35B, whereas US Patent No. ‘12,053,515 1’ is directed to serotypes 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20, 22F, 23B, 23F, 24F, 33F and 35B. Applicants state that serotypes 11A, 17F, 19F, 20, and 23B of the US cited patent are not present in Applicants’ claims. Applicants argue that the composition of the US patent is very clearly different from Applicants’ claimed composition and does in no way suggest Applicants’ composition as recited in the claims. Applicants’ arguments have been carefully considered, but are not persuasive. The following statement of Applicants’ has been noted: ......... if deemed necessary and upon the otherwise allowance of the claims, Applicant will submit an eTerminal Disclaimer. As set forth previously in detail, the transitional limitation “comprising” similar to the limitations such as “having” “including,” “containing,” or “characterized by” represents open-ended claim language and therefore does not exclude additional, unrecited elements. See M.P.E.P 2111.03 [R-1]. See Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986); In re Baxter, 656 F.2d 679, 686, 210 USPQ 795, 803 (CCPA 1981); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948) (“comprising” leaves “the claim open for the inclusion of unspecified ingredients even in major amounts”). On the other hand, the limitation “consisting of” represents closed claim language and excludes any element, step, or ingredient not specified in the claim. In re Gray, 53 F.2d 520, 11 USPQ 255 (CCPA 1931); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948). In the instant case, the ‘515 patent’s composition “comprises” therein the conjugates of PEGylated capsular polysaccharides of all of the recited 25 different serotypes of S. pneumoniae as claimed by Applicants. Clearly, the identified claims of the ‘515 patent read on Applicants’ claims. Again, it is noted that the interpretation of the open claim language “comprising” as documented on page 4 of 5 of the Australian Examination report No. 2 (Applicants’ IDS), set forth below, is also consistent with that of the Office [Emphasis added]: ..... the term ‘comprising’ is considered non-exhaustive in this context. Therefore, an immunogenic composition ‘comprising’ 25 different serotypes comprises the 25 serotypes and can comprise of other serotypes. 14) The provisional rejection of claims 1-5, 7-9, 11-17, 20, 21 and 33 set forth in paragraph 29 of the Office Action mailed 07/11/25 and maintained in paragraph 20 of the Office Action mailed 01/28/26 under the judicially created doctrine of obviousness-type double patenting over claims 15, 1-15 and 16-24 of the co-pending 19070661 application in view of Porambo et al. (US 20200282040 A1 filed 09/07/2017, of record) is maintained. Applicants contend that Applicants’ composition is directed to serotypes 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 12F, 14, 15A, 15B, 15C, 16F, 18C, 19A, 22F, 23F, 24F, 33F, and 35B, whereas the cited US patent application is directed to serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6C, 6D, 7B, 7C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F, 20, 21, 22A, 22F, 23A, 23B, 23F, 24F, 27, 28A, 31, 33F, 34, 35A, 35B, 35F and 38. Applicants state that serotypes 11A, 17F, 19F, 20 of the cited US patent application and serotypes 6A, 6D, 7B, 7C, 11A, 17F, 19F, 20, 21, 22A, 23A, 23B, 27, 28A, 31, 34, 35A, 35F and 38 of Porambo are not present in Applicants’ claims. Applicants argue that these are clearly different compositions and do not suggest Applicants’ claimed invention. Applicants’ arguments have been carefully considered, but are not persuasive. Applicants’ are referred to the paragraph supra with regard to the transitional limitation “comprising”, which is similar to the limitations such as “having” “including,” “containing,” or “characterized by” represents open-ended claim language and therefore does not exclude additional, unrecited elements. See M.P.E.P 2111.03 [R-1]. See Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986); In re Baxter, 656 F.2d 679, 686, 210 USPQ 795, 803 (CCPA 1981); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948) (“comprising” leaves “the claim open for the inclusion of unspecified ingredients even in major amounts”). On the other hand, the limitation “consisting of” represents closed claim language and excludes any element, step, or ingredient not specified in the claim. In re Gray, 53 F.2d 520, 11 USPQ 255 (CCPA 1931); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948). In the instant case, the composition claimed in the co-pending ‘661 application as modified by Porambo et al. renders obvious the instantly claimed composition as set forth previously. The rejection stands. The following statement of Applicants’ has been noted: .... if deemed necessary and upon the otherwise allowance of the claims, Applicant will submit an eTerminal Disclaimer. Rejection(s) under 35 U.S.C § 103 Maintained 15) The following is a quotation of 35 U.S.C § 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 148 USPQ 459, that are applied for establishing a background for determining obviousness under 35 U.S.C § 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or unobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were effectively filed absent any evidence to the contrary. Applicants are advised of the obligation under 36 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned at the time a later invention was effectively filed in order for the examiner to consider the applicability of 35 U.S.C § 102(b)(2)(c) for any potential 35 U.S.C § 102(a)(2) prior art against the later invention. 16) The rejection of claims 1-5, 7-9, 11-17, 20, 21 and 33 set forth in paragraph 28 of the Office Action mailed 07/11/25 and maintained in paragraph 26 of the Office Action mailed 01/28/26 under 35 U.S.C § 103 as being unpatentable over Fairman et al. (US 11951165 B2 filed 07/01/2019, of record) (‘185) in view of WO 201827177 A1, published 12/13/2018 (WO ‘177, of record) is maintained. It is noted that this specific art rejection still remains unaddressed by Applicants. The fact that this rejection remains unaddressed was brought to Applicants’ attention at the bottom of page 9 of the previous Office Action mailed 01/28/26 at paragraph 26 therein. Yet, on pages 8-10 of their Remarks filed 04/23/26, once again, Applicants present arguments on a non-existent and non-pending obviousness rejection of claims 1-5, 7-9, 11-17, 20, 21 and 33 over “Fairman (U.S. Application Publication No. 2018/0333484) in view of W177 .....”. For the record again, no such rejection over “Fairman (U.S. Application Publication No. 2018/0333484) in view of W177 .....” under 35 U.S.C § 103 was made in paragraph 28 of the Office Action mailed 07/11/2025. The rejection statement that was set forth at paragraph 28 of the Office Action mailed 07/11/2025 is reproduced below, which does not include the primary reference of “Fairman (U.S. Application Publication No. 2018/0333484)” as alleged: PNG media_image2.png 66 549 media_image2.png Greyscale Further, it must be noted that the applied primary reference is US patent 11951165 B2, issued from the U.S. application 16459303, has a Continuation-in-Part relationship with the U.S application 15859251. The applied art of US patent 11951165 B2 is not the same as the U.S. Application Publication No. 2018/0333484 that Applicants are referring to. Rejection(s) under 35 U.S.C § 112(a) or (Pre-AIA ) First Paragraph 17) The following is a quotation of 35 U.S.C § 112(a): (a) IN GENERAL. - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C § 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out the invention. 18) Claim 33 is rejected under 35 U.S.C § 112(a) or 35 U.S.C § 112 (pre-AlA), first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 33, as amended, is set forth below, which lacks descriptive support in the as-filed specification: PNG media_image1.png 71 580 media_image1.png Greyscale Applicants contend that the incorporation of homo multifunctional PEGylated cross linker ‘in a composition’ is disclosed in page 13 of the specification. Applicants state that claim 33 has been amended to recite that the carrier protein is covalently connected to bacterial capsular polysaccharides ‘by’ homo multifunctional PEGylated cross linkers “exactly as recited” in the specification at page 13. However, the relevant parts of page 13 of the specification exactly recite the following [Emphasis in bold]: A preferred formulation of the immunogenic composition comprises at least 25 different serotypes of bacterial capsular polysaccharides of Streptococcus pneumoniae covalently connected to carrier protein through, preferably, PEGylated linker compounds. The carrier protein is covalently connected to bacterial capsular polysaccharides through a number of multifunctional PEG linkers, which may be homo-multi-functional or hetero-multi-functional, and preferably of defined lengths. Therefore, the above-identified limitations and the currently claimed scope of the claim constitute new matter. See M.P.E.P 608.04 to 608.04(c). Applicants are requested to point to the descriptive support in the specification as filed, for the new limitation(s), or alternatively, remove the new matter from the claim(s). Applicants should specifically point out the support for any amendments made to the disclosure. See MPEP 714.02 and 2163.06, which, with respect to newly added or amended claims, requires Applicants to show support in the original disclosure for the new or amended claims. Alternatively, it is suggested that Applicants replace the above-identified added limitations with the limitations --wherein the capsular polysaccharides of the S. pneumoniae serotypes indirectly coupled to the one or more carrier proteins through ....--. 19) Claims 1-5, 7-9, 11-17, 20, 21, 31 and 33 are rejected under 35 U.S.C § 112(a) or 35 U.S.C § 112 (pre-AlA), first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claims 1 and 11, as amended, include the added limitations: the ‘total polysaccharides and protein per dose’ which lack sufficient descriptive support in the as-filed specification. Applicants state that they have amended claims 1 and 10 to exactly confirm to the wording of claims 10 and 11. However, first, there is no pending claim 10 in the instant application since Applicants canceled claim 10 previously. Second, the original claims 10 and 11, each depend from the original claim 1, which claim 1 is significantly different from the instantly amended claim 1 both scope-wise and language-wise. With no antecedence, ‘total polysaccharides and protein per dose’ recited in those claims 10 and 11 comprised in the immunogenic composition are not required to be the specific 25 different S. pneumoniae serotype capsular polysaccharides coupled to the carrier protein comprised in the immunogenic composition of claim 1 and therefore encompass generic total polysaccharides and generic protein including those that are uncoupled and/or non-covalently coupled. Therefore, the above-identified limitations in the claim(s) and/or the current scope of the claim(s) constitute new matter. See M.P.E.P 608.04 to 608.04(c). Applicants are requested to point to the descriptive support in the specification as filed, for the new limitation(s), or alternatively, remove the new matter from the claim(s). Applicants should specifically point out the support for any amendments made to the disclosure. See MPEP 714.02 and 2163.06, which, with respect to newly added or amended claims, requires Applicants to show support in the original disclosure for the new or amended claims. Alternatively, if Applicants’ intention is to convey that the recited 10 micrograms or less, or the recited 4 micrograms comprised in the dose is of the total capsular polysaccharides indirectly coupled to the one or more carrier proteins per dose, then it is suggested that Applicants replace the above-identified added limitations with the limitations --wherein the total capsular polysaccharides indirectly coupled to the one or more carrier proteins per dose--. Rejection(s) under 35 U.S.C § 112(b) or (Pre-AIA ) Second Paragraph 20) The following is a quotation of 35 U.S.C § 112(b): (B) CONCLUSION --The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 21) Claims 1-5, 7-9, 11-17, 20, 21, 31 and 33 are rejected under 35 U.S.C § 112(b) or 35 U.S.C § 112 (pre-AIA ), second paragraph, as being indefinite, for failing to particularly point out and distinctly claim the subject matter which inventor or a joint inventor or for the pre-AIA the Applicants regard as the invention. (a) Claim 1, as amended, is indefinite for having an antecedence issue with regard to the limitation “protein”. See line 11. It is unclear whether or not this ‘protein’ is any generic protein uncoupled or non-covalently coupled, or the earlier recited one or more carrier proteins covalently indirectly coupled to the capsular polysaccharides of the 25 different serotypes S. pneumoniae? Without a proper antecedence, one of ordinary skill cannot ascertain the metes and bounds of the claim. (b) Analogous rejection applies to the dependent claim 11, as amended, with regard to the limitation “protein”. See line 2. (c) Claim 33, as amended, is indefinite for having antecedent issues with regard to the limitations “the carrier protein” and “bacterial capsular polysaccharides”. Claim 33, as amended, depends from claim 1, as amended, wherein the capsular polysaccharides are not any generic bacterial capsular polysaccharides, instead are limited to --the capsular polysaccharides-- of 25 different serotypes of S. pneumoniae coupled indirectly not to a carrier protein, but to --the one or more carrier proteins--. (d) Claims 2-5, 7-9, 11-17, 20, 21, 31 and 33, which depend directly or indirectly from claim 1, are also rejected as being indefinite due to the indefiniteness identified supra in the base claim. Conclusion 22) No claims are allowed. To be consistent with the description in the as-filed specification and for clarity, it is suggested that Applicants replace the limitation “with” in line 2 of the claim with the limitation --through--. Correspondence 23) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner’s voice mail system. The Examiner is on a flexible work schedule, however she can normally be reached Monday to Friday from 8.00 a.m. to 4.00 p.m. (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor Jeffrey Stucker, can be reached at (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned (571) 273-8300. 24) Information regarding the status of an application may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center or Private PAIR to authorized users only. Should you have questions about access to Patent Center or the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. /S. DEVI/ S. Devi, Ph.D.Primary Examiner Art Unit 1645 May, 2026
Read full office action

Prosecution Timeline

Show 24 earlier events
Jul 11, 2025
Non-Final Rejection mailed — §112
Oct 12, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §112
Apr 23, 2026
Request for Continued Examination
Apr 24, 2026
Response after Non-Final Action
Jun 03, 2026
Non-Final Rejection mailed — §112
Aug 15, 2026
Response Filed
Nov 10, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788792
METHOD FOR TREATING A SKIN WOUND CONTAINING KLEBSIELLA PNEUMONIAE
2y 2m to grant Granted Nov 10, 2026
Patent 12758624
INDUSTRIAL PRODUCTION METHOD FOR STAPHYLOCOCCUS AUREUS VACCINE
2y 9m to grant Granted Oct 13, 2026
Patent 12746261
PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE
3y 6m to grant Granted Sep 29, 2026
Patent 12697379
PEGYLATED TETANUS NEUROTOXINS AND TREATMENT OF HYPOTONIA
5y 6m to grant Granted Aug 04, 2026
Patent 12699090
DIAGNOSTIC REAGENTS
4y 10m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

11-12
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+55.6%)
High
PTA Risk
Based on 884 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month